Endocrinol Metab.  2024 Jun;39(3):531-533. 10.3803/EnM.2024.2002.

Beyond Bone: Embracing Osteosarcopenia for Comprehensive Fracture Prevention

• Kim BJ

• KMID: 2556645
• DOI: http://doi.org/10.3803/EnM.2024.2002

Figure

• 

  Fig. 1. Therapeutic approaches independently targeting either sarcopenia or osteoporosis may not be sufficient for effective fracture prevention.

Reference

1. Ahn SH, Park SM, Park SY, Yoo JI, Jung HS, Nho JH, et al. Osteoporosis and osteoporotic fracture fact sheet in Korea. J Bone Metab. 2020; 27:281–90.

2. Ji S, Jung HW, Baek JY, Jang IY, Lee E. Sarcopenia as the mobility phenotype of aging: clinical implications. J Bone Metab. 2024; 31:1–12.

3. Chen S, Xu X, Gong H, Chen R, Guan L, Yan X, et al. Global epidemiological features and impact of osteosarcopenia: a comprehensive meta-analysis and systematic review. J Cachexia Sarcopenia Muscle. 2024; 15:8–20.

4. Tagliaferri C, Wittrant Y, Davicco MJ, Walrand S, Coxam V. Muscle and bone, two interconnected tissues. Ageing Res Rev. 2015; 21:55–70.

5. Cariati I, Bonanni R, Onorato F, Mastrogregori A, Rossi D, Iundusi R, et al. Role of physical activity in bone-muscle crosstalk: biological aspects and clinical implications. J Funct Morphol Kinesiol. 2021; 6:55.

6. Bettis T, Kim BJ, Hamrick MW. Impact of muscle atrophy on bone metabolism and bone strength: implications for muscle-bone crosstalk with aging and disuse. Osteoporos Int. 2018; 29:1713–20.

7. Kim BJ. Effects of muscles on bone metabolism-with a focus on myokines. Ann Geriatr Med Res. 2022; 26:63–71.

8. Battafarano G, Rossi M, Marampon F, Minisola S, Del Fattore A. Bone control of muscle function. Int J Mol Sci. 2020; 21:1178.

9. Kirk B, Zanker J, Duque G. Osteosarcopenia: epidemiology, diagnosis, and treatment-facts and numbers. J Cachexia Sarcopenia Muscle. 2020; 11:609–18.

10. Hirschfeld HP, Kinsella R, Duque G. Osteosarcopenia: where bone, muscle, and fat collide. Osteoporos Int. 2017; 28:2781–90.

11. Gielen E, Dupont J, Dejaeger M, Laurent MR. Sarcopenia, osteoporosis and frailty. Metabolism. 2023; 145:155638.

12. Kirk B, Miller S, Zanker J, Duque G. A clinical guide to the pathophysiology, diagnosis and treatment of osteosarcopenia. Maturitas. 2020; 140:27–33.

13. Yoo JI, Kim H, Ha YC, Kwon HB, Koo KH. Osteosarcopenia in patients with hip fracture is related with high mortality. J Korean Med Sci. 2018; 33:e27.

14. Bae S, Lee S, Park H, Ju Y, Min SK, Cho J, et al. Position statement: exercise guidelines for osteoporosis management and fall prevention in osteoporosis patients. J Bone Metab. 2023; 30:149–65.

15. Polito A, Barnaba L, Ciarapica D, Azzini E. Osteosarcopenia: a narrative review on clinical studies. Int J Mol Sci. 2022; 23:5591.

16. Bonnet N, Bourgoin L, Biver E, Douni E, Ferrari S. RANKL inhibition improves muscle strength and insulin sensitivity and restores bone mass. J Clin Invest. 2019; 129:3214–23.

17. Phu S, Bani Hassan E, Vogrin S, Kirk B, Duque G. Effect of denosumab on falls, muscle strength, and function in community-dwelling older adults. J Am Geriatr Soc. 2019; 67:2660–1.

18. Park SJ, Ji E, Yoo HJ, Kim K, Ji S, Baek JY, et al. Circulating lumican as a potential biomarker for osteosarcopenia in older adults. Bone. 2024; 179:116959.